CSL Limited Share Price: Aussie Biotech Giant Faces $17 Billion Hit as U.S. Vaccine Demand Falls
In recent weeks, the CSL share price has come under intense pressure as Australia’s biotech powerhouse confronts weakening U.S. vaccine demand, driving a dramatic shift in investor sentiment. Once regarded as a stable performer among healthcare stocks, CSL now faces a sharp reassessment of its growth prospects and strategic direction.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
